Morning Market Movers - Brainstorm Cell (NASDAQ:BCLI), Quest Diagnostics (NYSE:DGX)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Brainstorm Cell Therapeutics Inc.(NASDAQ: BCLI) shares surged 73.11% to $8.24 ahead of January 5 conference call to discuss final results of Phase 2a trial of NurOwn in ALS.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Perfect World Co., Ltd. (NASDAQ: PWRD) shares gained 15.48% to $18.20 after the company reported Chairman's preliminary non-binding 'go-private' offer at $20 per ADS. The company also named Yunfan Zhang as COO. Regulus Therapeutics Inc. (NASDAQ: RGLS) shares rose 7% to $17.16. Regulus Therapeutics shares have jumped 117.94% over the past 52 weeks, while the S&P 500 index has gained 12.39% in the same period. NeuroDerm Ltd.

Want Private Access to Benzinga Analyst?

Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.

(NASDAQ: NDRM) shares rose 4.63% to $14.69 after tumbling 22.60% on Wednesday. Kite Pharma, Inc.

(NASDAQ: KITE) shares gained 3.49% to $59.68. Credit Suisse reiterated an Outperform rating on Kite Pharma and raised the price target from $34.00 to $71.00. Rite Aid Corporation (NYSE: RAD) shares gained 3% to $7.75 after the company reported December same-store sales. Total drugstore sales for the four-week period increased 4.9 percent to $2.212 billion compared to $2.109 billion for the same period last year. Fidelity National Financial, Inc. (NYSE: FNF) shares climbed 2.64% to $35.36. Stephens & Co. upgraded Fidelity National from Equal-weight to Overweight and raised the price target from $31.00 to $43.00. Quest Diagnostics Inc. (NYSE: DGX) shares rose 2.59% to $68.80. Raymond James upgraded Quest Diagnostics from Underperform to Market Perform.